Company
Headquarters: Qianjiang, China
CN¥2.75 Billion
CNY as of July 1, 2024
US$378.9 Million
| Company | Market Cap (USD) |
|---|---|
| Lilly | $808.65 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $450.89 B |
| Johnson & Johnson | $350.63 B |
| Merck | $318.75 B |
Zhongzhu Healthcare Holding Co.,Ltd constructs and develops real estate properties in China. It also produces ophthalmic drugs; researches and develops natural botanical drugs. In addition, it researches and develops drugs, such as recombinant human endostatin adenovirus injection, which is an anticancer gene therapy; Genistein capsule for the treatment of postmenopausal osteoporosis; and motherwort that is primarily a gynecological drug. Further, the company offers medical instruments, including radiation therapy, hyperthermia, phototherapy, and ultrasound diagnosis, as well as develops imaging breast tumor detection systems. Additionally, it offers medical services. The company was formerly known as Zhongzhu Holding Co., Ltd. and changed its name to Zhongzhu Healthcare Holding Co.,Ltd in June 2016. Zhongzhu Healthcare Holding Co.,Ltd was founded in 1970 and is headquartered in Qianjiang, China.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Zhongzhu Healthcare Holding Co.,Ltd has the following listings and related stock indices.
Stock: SSE: 600568 wb_incandescent